戻る Agenda
Biosimilar Interchangeability: A Global Perspective
Session Chair(s)
Nielsen Hobbs
Executive Editor, The Pink Sheet, United States
Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.
Learning Objective : Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.
Speaker(s)
Regulatory Perspective
Steinar Madsen, MD
Medical Director, Norwegian Medicines Agency, Norway
Panelist
Molly Burich, MPH
Director, Public Policy: Biosimilars and Reimbursement, Boehringer Ingelheim Pharmaceuticals, Inc, United States
Panelist
Chad Pettit, MBA
Executive Director, Marketing, Global Biosimilars Commercial Lead, Amgen Inc., United States